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0929-6646/Copyright ª 2014, ElsevierBackground/Purpose: Acanthamoeba keratitis is difficult to treat because Acanthamoeba cysts
are resistant to the majority of antimicrobial agents. Despite the efficacy of 0.02% chlorhexi-
dine in treating Acanthamoeba keratitis, a lack of data in the literature regarding the formu-
lation’s stability limits its clinical use. The objective of this study was to develop an optimal
extemporaneous 0.02% chlorhexidine digluconate ophthalmic formulation for patients in need.
Methods: With available active pharmaceutical ingredients, 0.02% chlorhexidine digluconate
sample solutions were prepared by diluting with BSS Plus Solution or acetate buffer. Influences
of the buffer, type of container, and temperature under daily-open condition were assessed
based on the changes of pH values and chlorhexidine concentrations of the test samples
weekly. To determine the beyond-use date, the optimal samples were stored at 2e8C or room
temperature, and analyzed at time 0 and at Week 1, Week 2, Week 3, Week 4, Week 5, Week 8,
Week 12, and Week 24.
Results: Despite chlorhexidine exhibiting better stability in acetate buffer than in BSS solution,
its shelf-life was < 14 days when stored in a light-resistant low-density polyethylene container.
The acetate-buffered 0.02% chlorhexidine digluconate solution stored in light-resistant high-
density polyethylene eyedroppers did not exhibit significant changes in pH or strength at
any time interval.
Conclusion: The acetate-buffered 0.02% chlorhexidine digluconate ophthalmic solution stored
in light-resistant high-density polyethylene eyedroppers demonstrated excellent stability at 2have no conflicts of interest relevant to this article.
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Formulation of an extemporaneous chlorhexidine eye drop 1163Figure 1 Chemical structure of ce25C for 6 months after being sealed and for 1 month after opening. This finding will enable
us to prepare 0.02% chlorhexidine digluconate ophthalmic solutions based on a doctor’s pre-
scription.
Copyright ª 2014, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Acanthamoeba keratitis, a corneal infectious disease, is
difficult to treat because Acanthamoeba cysts are resistant
to the majority of existing antimicrobial agents. Compared
with other pharmaceutical agents, biguanides have the
lowest minimal amebicidal and cysticidal concentration,
and 0.02% biguanide ophthalmic preparations are the drug
of choice for Acanthamoeba keratitis.1,2 However, these
products are not commercially available in Taiwan.
Chlorhexidine is a biguanide (Fig. 1) and the drug of
choice for Acanthamoeba keratitis.3 It is a strong base,
practically insoluble in water at 20C, and available in
different salt forms, including dihydrochloride, diacetate,
and digluconate. Different chlorhexidine salts have varying
water solubilities.4,5 Chlorhexidine digluconate is freely
soluble in water, is manufactured as a 20% w/v stock
aqueous solution, and should be protected from light during
storage.6 Some licensed 20% chlorhexidine digluconate
products obtained from domestic manufacturers and
chlorhexidine digluconate concentrate imported from the
reagent supplier Sigma-Aldrich (Steinheim, Germany) can
be used as raw materials.
Chlorhexidine digluconate is extensively used as an
antiseptic because of its broad-spectrum coverage of Gram
(þ) and Gram () bacteria.7 Chlorhexidine 0.005% has been
used as a pharmaceutical preservative, particularly in
ophthalmic solutions.5,6 However, high concentrations of
chlorhexidine are irritating to mucous membranes, and a
concentration not to exceed 0.05% is recommended when
applied to wounds and burns to decrease the risk of
anaphylactic reaction.8 Recently, several studies have
demonstrated that 0.02% chlorhexidine possesses excellent
amebicidal activity and minimal corneal epithelial
toxicity.1e3 Despite reports of the efficacy of 0.02% chlor-
hexidine in the treatment of Acanthamoeba keratitis, a
lack of data in the literature regarding the formulation’s
stability limits its clinical use. To the best of our knowl-
edge, only Moorfields Pharmaceuticals (London) in the
United Kingdom has commercialized 0.02% chlorhexidine
ophthalmic products. Ordering the product from abroad is
not only expensive, but also labor and time intensive, which
may result in a delay in treatment. Therefore,hlorhexidine digluconate.extemporaneous compounding of chlorhexidine digluconate
0.02% ophthalmic solutions is needed in Taiwan.
The aim of this study was to develop an optimal
extemporaneous 0.02% chlorhexidine digluconate
ophthalmic formulation with an appropriate pH value and
osmolality for patients with Acanthamoeba keratitis, to
ensure that the sterility, particulate matter, and assay of
the final product meet the general characteristics of
ophthalmic solutions in pharmacopoeia, and to determine
the type of container, storage condition, and beyond-use
date of the final product. This is the very first report on
the formulation and stability of an optimal extemporaneous
chlorhexidine digluconate 0.02% ophthalmic solution. Our
hospital, with 60-year experiences in extemporaneous
compounding and in-house quality control for medications,
would like to share this formula with the world.9e12
Methods
Materials
Chlorhexidine acetate standard was obtained from US Phar-
macopeia (USP; Rockville, MD, USA). Chlorhexidine digluco-
nate 20% was provided by Schutz Dishman Biotech Limited
(Ahmedabad, India). Anhydrous sodiumacetate (CH3COONa),
glacial acetic acid (CH3COOH), sodium dihydrogen phosphate
monohydrate (NaH2PO4.H2O), triethylamine, and acetoni-
trile were purchased from Merck (Darmstadt, Germany).
Light-resistant low-density polyethylene (LDPE) containers
for ophthalmic solutions were provided by Sinphar (I-Lan,
Taiwan), and light-resistant high-density polyethylene
(HDPE) containers were provided by Chin-Tai Plastic Ind. Co.,
Ltd (Changhua, Taiwan). Balanced salt solution (BSS Plus So-
lution), which contains sodium chloride, potassium chloride,
calcium chloride, magnesium chloride hexahydrate, sodium
acetate, and sodium citrate, was obtained from Alcon Labo-
ratories, Inc. (Fort Worth, TX, USA).
Experimental design and sample preparation
With available active pharmaceutical ingredients, we
formulated a 0.02% chlorhexidine digluconate ophthalmic
solution and investigated the effects of temperature and
buffer on its stability in two types of containers, HDPE
eyedroppers and LDPE eyedroppers. Other parameters,
such as pH value, osmolality, particulate matter concen-
tration, and sterility, were also assessed. The beyond-use
date was determined through these tests.
Experimental implementation of various physical condi-
tions encountered clinically is listed in Table 1 and can be
divided into three stages. In the first stage, eight sets of
Table 1 Experimental design for developing an optimal 0.02% chlorhexidine digluconate ophthalmic preparation.
Experiment
stage
Solvent Type of
container
Storage
temperature
Opened thrice daily or
sealed
Test time point
1 Acetate buffer LDPE RT Opened thrice daily D0, W1, W2, W3, W4
Acetate buffer LDPE 2e8C Opened thrice daily D0, W1, W2, W3, W4
Acetate buffer LDPE RT Sealed D0, W4
Acetate buffer LDPE 2e8C Sealed D0, W4
BSS LDPE RT Opened thrice daily D0, W1, W2, W3, W4
BSS LDPE 2e8C Opened thrice daily D0, W1, W2, W3, W4
BSS LDPE RT Sealed D0, W4
BSS LDPE 2e8C Sealed D0, W4
2 Acetate buffer Glass RT Opened thrice daily D0, W1, W2
Acetate buffer HDPE RT Opened thrice daily D0, W1, W2
3 Acetate buffer HDPE RT Opened thrice daily D0, W1, W2, W3, W4, W5
Acetate buffer HDPE 2e8C Opened thrice daily D0, W1, W2, W3, W4, W5
Acetate buffer HDPE RT Sealed D0, W4, W8, W12, W24
Acetate buffer HDPE 2e8C Sealed D0, W4, W8, W12, W24
BSS Z balanced salt solution; D0 Z Day 0; HDPE Z high-density polyethylene; LDPE Z low-density polyethylene; RT Z room tem-
perature; W1Z Week 1; W2Z Week 2; W3Z Week 3; W4Z Week 4; W5Z Week 5; W8Z Week 8; W12Z Week 12; W24Z Week 24.
Figure 2 Formulation development and stability evaluation.
BSS Z balanced salt solution; HDPE Z high-density poly-
ethylene; LDPE Z low-density polyethylene.
1164 S.-C. Lin et al.test samples were used to study the influence of buffer and
temperature under daily-open or sealed conditions. Six test
samples were prepared for every condition at each test
time point. Three of them were used for pH value mea-
surement and high-performance liquid chromatography
(HPLC) analysis, and the others for sterility tests. Further-
more, the amount of particulate matter and osmolality
were measured every 4 weeks, so another six test samples
were prepared for Week 4 in every sample set, three for
particulate matter measurement and the others for osmo-
lality measurement. In the second stage, triplicate 0.02%
acetate-buffered chlorhexidine digluconate test samples
were prepared, stored in glass and HDPE containers, and
analyzed on Day 0, Week 1, and Week 2. In the third stage,
the stability of the final products was studied. Four sets of
test samples were prepared and analyzed on Day 0 and
Week 1, Week 2, Week 3, Week 4, Week 5, Week 8, Week
12, and Week 24. The study items at each test time point
were the same as those in the first stage.
Test samples for chlorhexidine digluconate (0.2 mg/mL)
solution was prepared by dilution with either acetate
buffer (composed of 141.4mM CH3COONa and 7.8mM
CH3COOH) or BSS Plus Solution in a laminar flow cabinet in
an ISO class 5 clean room using an aseptic technique. After
mixing, the solutions were filtered through a 0.22 mm
membrane and stored in the eyedroppers. Each dropper
was filled with 10 mL of the test sample. Influences of the
buffer, type of container, and temperature under daily-
open or sealed conditions were studied. The stability at
room temperature was determined in a laboratory where
the humidity was 52e65%, and the temperature was <25C
in the daytime and 25e28C during the evening and night-
time. The schema in Fig. 2 presents the development of the
formulation and the evaluation of its stability.
We simulated the contact time of the solution to the air
in clinical settings by study design. In the daily-open
groups, we opened the eyedroppers thrice daily (at
9:00 AM, 1:00 PM, and 5:00 PM), shook them for a while, and
let the eyedroppers stand for 10 minutes prior to beingclosed. Thus, the total time of exposure of the test samples
to the environment, 30 minutes per day, was not signifi-
cantly different from clinical scenarios where a 0.02%
chlorhexidine ophthalmic solution is given every 2 hours.
Analysis by HPLC
Chlorhexidine digluconate was assayed by an HPLC method
according to the USP. This method was validated for
determining chlorhexidine digluconate in various pharma-
ceutical formulations.13 To achieve the optimal perfor-
mance, the flow rate and mobile phase composition of the
method were slightly modified.
The HPLC system was an Agilent 1100 LC (Agilent Tech-
nologies, Santa Clara, CA, USA) comprising a G1329A
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nary pump, a G1315B diode array detector, and Chem-
iStation software. A reversal C18 column (LiChroCART 250-4
LiChroSphere C18, 250 mm  4 mm, particle size 5 mm) from
Merck was set at a temperature of 40C. The detector was
operated at a wavelength of 239 nm, and the injection
volume of the sample was 50 mL.
Mobile phase A was prepared by dissolving 27.6 g of
monobasic sodium phosphate monohydrate and 5 mL of
triethylamine in 750 mL of water (adjusted to a pH of 3.0
using phosphoric acid), diluting with water to 2 L, and
mixing the resulting solution with acetonitrile (70:30). Mo-
bile phase B was acetonitrile. The gradient setting was as
follows: isocratic with 100% mobile phase A for 7 minutes,
linear gradient to 50% mobile phase A from 7 minutes to 22
minutes, isocratic at 50% mobile phase A from 22 minutes to
27 minutes, linear gradient to 0% mobile phase B from 27
minutes to 27.1 minutes, and finally isocratic with 100%
mobile phase A from 27.1 minutes to 35 minutes. The total
running time was 35 minutes at a flow rate of 1.2 mL/
minute. The retention time of chlorhexidine was 15
minutes.
The chlorhexidine acetate reference standard (molecu-
lar weight 625.55) 0.25 mg/mL stock solution was prepared
in a 100 mL volumetric flask by dilution with mobile phase
A. Working solutions of chlorhexidine acetate were pre-
pared by diluting the stock solution with mobile phase A to
six concentrations ranging from 0.01 mg/mL to 0.06 mg/mL.
Quality control samples were included in each analytical
sequence in triplicate to ensure the linearity, intraday
precision, interday precision, and accuracy of the analysis.
A calibration curve was constructed by plotting the peak
area of chlorhexidine as a function of the chlorhexidine
acetate concentration (range 0.01e0.06 mg/mL). Prior to
injection, 3 mL of the 0.02% chlorhexidine digluconate eye-
drop samples were pipetted accurately into a 10 mL volu-
metric flask and diluted to volume with mobile phase A.
Triplicate HPLC determinations were performed on all the
samples of each test solution.
The initial concentrations (time 0) of chlorhexidine
digluconate were referenced as 100%, and all subsequent
concentrations were expressed as percentages of the initial
concentration. The stability of the chlorhexidine gluconate
in the ophthalmic solution was assessed by evaluating the
percent change in the concentration from time 0. A
decrease of more than 10% of the initial concentration was
considered a significant loss of the drug.Measurements of pH value, sterility, particulate
matter, and osmolality
The pH value was measured by a Radiometer PHM210 pH
meter (Radiometer, Lyon, France). The concentration of
particulate matter was measured by APS 2000 (Particle
Measuring Systems, Boulder, CO, USA). The osmolality was
measured by an automatic autocal micro-osmometer
(Roebling, Berlin, Germany).
Microbial contamination of each sample was determined
according to the USP sterility test using sterility-testing
accessories, and microbiological media were purchased
from Pall Corporation (New York, NY, USA).Results
In this study, an optimal 0.02% extemporaneous chlorhexi-
dine digluconate ophthalmic formulation, with a pH of 5.9
and an osmolality of 270 mOsmol/kg, was developed. When
stored at 2e25C, the formulation has a 6-month beyond-
use date when sealed in a light-resistant HDPE dropper, and
is stable for 1 month when opened for 10 minutes thrice
daily.
Stability of chlorhexidine digluconate in BSS or
acetate buffer stored in LDPE containers
The osmolality of the 0.02% chlorhexidine digluconate eye
drops in BSS was 300 mOsmol/kg and remained unchanged
during the testing period. However, the pH value increased
from 7.7 to 8.3, and the concentration decreased drasti-
cally and was undetectable on Day 7 when stored at room
temperature, as well on Day 14 when stored at 2e8C
(Fig. 3). The concentration of particulate matter measured
in BSS was higher than that measured in the acetate buffer.
The pH value and osmolality of the 0.02% chlorhexidine
solution in acetate buffer remained unchanged at near 5.9
and 270 mOsmol/kg, respectively, during the study period.
On Day 14, concentrations of chlorhexidine decreased by
> 10% from the initial value. Compared with the BSS solu-
tions, 0.02% chlorhexidine in acetate buffer exhibited
better stability, although its shelf-life was < 14 days when
stored in an LDPE container (Fig. 3).
Change of container
LDPE containers are the most commonly used eyedroppers.
However, these can adsorb chlorhexidine.6 A 2-week pre-
liminary test to examine the concentration changes of the
chlorhexidine gluconate solution in an acetate buffer
stored in non-LDPE containers found that the 0.02% chlor-
hexidine digluconate concentration remained unchanged
after 2 weeks. Therefore, an HDPE container was used for
the following studies.
Stability of the final products
When opened for 10 minutes thrice daily, the chlorhexidine
digluconate solution was stable throughout the 5-week
study period, irrespective of whether it was refrigerated
or stored at room temperature (Table 2). The chlorhexidine
digluconate solution remained stable for 24 weeks when
sealed in HDPE containers, regardless of whether it was
refrigerated or stored at room temperature (Table 3).
The pH value of the tested eye-drop samples in acetate
buffer was measured to be 5.9 initially and did not differ by
more than one-tenth of a pH unit over the study period. The
osmolality was similarly stable.
Ophthalmic solutions should be essentially free from
particles large enough to be observed on visual inspection.
The USP suggests that ophthalmic solutions should not
exceed concentrations of 50 pieces/mL and 5 pieces/mL for
particles 10 mm and 25 mm, respectively.14 Although the
amount of particulate matter in the 0.02% chlorhexidine
ophthalmic solutions increased slightly over time, it
Figure 3 Stability of 0.02% chlorhexidine digluconate solution using BSS or acetate buffer as the solvent in LDPE containers when
opened thrice daily. BSS Z balanced salt solution; conc. Z concentration; LDPE Z low-density polyethylene.
1166 S.-C. Lin et al.remained within an acceptable range (Table 3, Fig. 4). No
microbial contamination was evident under any of the
experimental conditions.Discussion
Formulation development
Preparation of ophthalmic solutions requires careful
consideration of isotonicity and buffering agents. According
to USP 34, an ideal ophthalmic solution should be isotonic
to a 0.9% sodium chloride solution (normal saline). How-
ever, the eyes can tolerate osmolalities ranging fromTable 2 Stability of a 0.02% chlorhexidine ophthalmic solution
daily.
Tests Day 0 Week 1 We
Initial concentration (%)
RT 100.0  1.7 102.8  2.0 97.
2e8C 102.3  5.9 98.
pH value
RT 5.95  0.01 5.92  0.01 5.9
2e8C 5.93  0.02 5.9
Particulate matter (pieces/mL)
RT 10 mm 0.1  0.2 NP NP
25 mm ND NP NP
2e8C 10 mm 0.1  0.2 NP NP
25 mm ND NP NP
Osmolality (mOsm/kg)
RT 270.1  0.6 NP NP
2e8C NP NP
Sterility
RT Sterile Sterile Ste
2e8C Sterile Ste
ND Z not detectable; NP Z not performed; RT Z room temperature190 mOsmol/kg (0.6% sodium chloride solution) to
650 mOsmol/kg (2.0% sodium chloride solution) without
marked discomfort.15,16
Normal tears have a pH of approximately 7.4 and possess
some buffering capacity, making ophthalmic solutions with
pH values between 3.5 and 8.5 acceptable.15 Aqueous so-
lutions of chlorhexidine are most stable within a pH range
of 5e8, and the optimal pH range for antimicrobial activity
is 5.5e7.0.6 The type of buffer solution is an essential
determinant of the safety and effectiveness of an eye drop.
Chlorhexidine digluconate cannot be diluted with normal
saline due to the low solubility of chlorhexidine hydro-
chloride (<1 mg/100 mL) and is incompatible with sodium
lauryl sulfate, sodium carboxymethyl cellulose, etc.6in a high-density polyethylene container when opened thrice
ek 2 Week 3 Week 4 Week 5
3  0.8 99.1  0.2 101.1  1.2 102.9  0.4
0  0.5 100.1  1.2 100.1  0.6 102.4  0.9
2  0.02 5.97  0.01 5.91  0.01 5.92  0.01
3  0.01 5.95  0.02 5.93  0 5.91  0.02
NP 1.7  0.6 NP
NP 0.1  0.2 NP
NP 1.0  1.7 NP
NP ND NP
NP 270.0  0 NP
NP 272.7  1.2 NP
rile Sterile Sterile Sterile
rile Sterile Sterile Sterile
.
Table 3 Stability of 0.02% chlorhexidine ophthalmic solutions in sealed HDPE containers under optimized conditions.
Examination items Initial conditions Open date of the sealed HDPE bottles
Day 0 Week 4 Week 8 Week 12 Week 24
Initial concentration (%)
RT 100.0  1.7 99.7  0.3 99.9  0.3 97.3  0.2 99.9  0.4
2e8C 100.0  0.1 99.8  0.2 97.1  0.4 98.8  0.7
pH value
RT 5.95  0.01 5.93  0.04 5.89  0.03 5.89  0.01 5.93  0.04
2e8C 5.89  0.01 5.93  0.04 5.87  0.02 5.96  0.04
Particulate matter (pieces/mL)
RT 10 mm 2.4  0.5 1.3  1.0 3.1  0.5 4.2  2.3 4.5  5.1
25 mm ND 0.1  0.2 ND 0.7  0.9 0.4  0.2
2e8C 10 mm 2.4  0.5 1.2  0.5 2.4  1.2 6.6  2.8 6.1  3.1
25 mm ND ND ND 0.1  0.2 0.6  0.4
Osmolality (mOsm/kg)
RT 270.1  0.6 273.0  0 273.3  0.3 272.8  0.3 272.7  1.2
2e8C 272.0  0 273.3  0.6 272.3  1.2 272.0  1.0
Sterility
RT Sterile Sterile Sterile Sterile Sterile
2e8C Sterile Sterile Sterile Sterile
HDPE Z high-density polyethylene; ND Z not detectable; RT Z room temperature.
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20% chlorhexidine digluconate raw material to 0.02%
chlorhexidine digluconate. The pH value of the 0.02%
chlorhexidine digluconate solution in water was 5.9, but
the osmolality was <10 mOsmol/kg. Because solutions of
low osmolality may cause irritation and swelling of
the cornea cells,17 addition of a buffering agent was
necessary to adjust the tonicity of the chlorhexidine eye
drops.
BSS Sterile Irrigating Solution is an isotonic solution for
eye irrigation. Because some hospitals use BSS to compound
the 0.02% chlorhexidine solution, it was included in our
study. By contrast, Denton6 found that sodium acetate mayFigure 4 Osmolality and particulate matter concentration of 0.
high-density polyethylene containers.be used to adjust the tonicity of chlorhexidine solutions
without causing precipitation; however, the pH value of the
buffered solution may be as high as 8.0. Therefore, acetic
acid was added to create an acetic acideacetate buffer
system. To prepare a solution with a pH value near 6, we
adjusted the concentrations of acetic acid and sodium ac-
etate according to the HendersoneHasselbach equation.18
Chlorhexidine solution is not only stable, but also exhibits
good antimicrobial activity at a pH value of about 6. After
optimizing the pH value and osmolality, the acetate buffer
solution comprising 141.4mM CH3COONa and 7.8mM
CH3COOH (pH 5.9, 270 mOsmol/kg) was included in our
study.02% chlorhexidine digluconate ophthalmic solutions sealed in
1168 S.-C. Lin et al.Compatibility of chlorhexidine digluconate with
BSS and acetate buffer
The content of chlorhexidine digluconate in BSS-buffered
solution stored in an LDPE eyedropper decreased drasti-
cally. The concentrations were close to 0 on Day 7 when
stored at room temperature, and on Day 14 when stored at
2e8C. However, the acetate-buffered chlorhexidine
digluconate solution in LDPE containers retained 90% of the
initial concentrations on Day 7, 60% on Day 14, and about
50% on Day 28. In addition, the amount of particulate
matter measured in BSS was higher than that measured in
the acetate buffer. Obviously, acetate buffer is a more
appropriate solvent than BSS to compound the 0.02%
chlorhexidine digluconate preparation. Moreover, chlor-
hexidine is incompatible with inorganic anions.6 BSS con-
tains approximately 0.13 mEq/mL chloride, which might
have made the BSS-buffered chlorhexidine digluconate so-
lution unstable. Therefore, we chose only acetate buffer as
a solvent for the 0.02% chlorhexidine digluconate prepara-
tion in the experiment of the next stage.
Influence of LDPE and HDPE containers on the
stability of chlorhexidine digluconate
Although the content of chlorhexidine digluconate in
acetate-buffered solution stored in a light-resistant LDPE
eyedropper decreased over a certain period of time, the
rate of decline slowed down after Day 14. The pH value did
not change despite the drop in concentrations. There may
be some factors other than buffer solutions that influenced
the stability of acetate-buffered chlorhexidine solution. A
statement “Low-density polyethylene may be unsuitable
(for chlorhexidine) because of excessive adsorption.” was
found in a textbook.6 Therefore, amber glass vials and
light-resistant HDPE eyedroppers were chosen in the second
stage. In the 2-week preliminary test, concentration of the
0.02% chlorhexidine digluconate remained unchanged. This
result confirmed our speculation that LDPE containers can
adsorb chlorhexidine. Therefore, the stability of the
optimal preparation, 0.02% chlorhexidine digluconate eye
drop in acetate buffer stored in light-resistant HDPE con-
tainers, was studied for 24 weeks in the third stage. The
results show that the formulation has an excellent stability
when stored in an HDPE eyedropper.Conclusion
This is the very first report on the formulation and stability
of an extemporaneous chlorhexidine digluconate 0.02%
ophthalmic solution. An optimal extemporaneous chlor-
hexidine digluconate 0.02% ophthalmic solution was pre-
pared by diluting a 20% chlorhexidine digluconate solution
with acetate buffer (pH 5.9 and osmolality 270 mOsmol/kg)
in a laminar flow hood in an ISO class 5 clean room, filtering
the resulting solution through a 0.22 mm membrane, and
dispensing into a sterile HDPE dropper aseptically. When
stored at 2e25C, the acetate-buffered 0.02% chlorhexi-
dine digluconate ophthalmic solution stored in light-
resistant HDPE eyedroppers demonstrated excellentstability for 6 months after being sealed, and for 1 month
after being opened. This stability will allow us to provide
0.02% chlorhexidine digluconate ophthalmic solutions to
patients suffering from Acanthamoeba keratitis based on a
doctor’s prescription.
Acknowledgments
This study was supported by a grant from the Department of
Health and the Ministry of Health and Welfare (DOH101-TD-
B-111-001), and was performed at the National Clinical Trial
and Research Center of the National Taiwan University
Hospital, Taipei, Taiwan. We acknowledge the work of as-
sistant Ya-Ting Hsieh in this study.
References
1. Dart JK, Saw VP, Kilvington S. Acanthamoeba keratitis: diag-
nosis and treatment update 2009. Am J Ophthalmol 2009;148:
487e99.
2. Lindquist TD. Treatment of Acanthamoeba keratitis. Cornea
1998;17:11e6.
3. Lim N, Goh D, Bunce C, Xing W, Fraenkel G, Poole TRG, et al.
Comparison of polyhexamethylene biguanide and chlorhexi-
dine as monotherapy agents in the treatment of Acanthamoeba
keratitis. Am J Ophthalmol 2008;145:130e5.
4. O’Neil MJ, Heckelman PE, Koch CB, Roman KJ, editors. The
Merck index: an encyclopedia of chemicals, drugs, and bi-
ologicals.. 14th ed. Whitehouse Station: Merck & Co., Inc.;
2006. p. 346.
5. Moore SL, Payne DN. Types of antimicrobial agents. In:
Fraise AP, Lambert PA, Maillard JY, editors. Russell, Hugo &
Ayliffe’s principles and practice of disinfection preservation &
sterilization. 4th ed. Oxford: Blackwell; 2004. p. 29e33.
6. Denton GW. Chlorhexidine. In: 5th ed., editor. Disinfection,
sterilization, and preservation. Philadelphia: Lippincott Wil-
liams & Wilkins; 2001. p. 321e33.
7. Milstone AM, Passaretti CL, Perl TM. Chlorhexidine: expanding
the armamentarium for infection control and prevention. Clin
Infect Dis 2008;46:274e81.
8. McEvoy GK, Snow EK, editors. AHFS drug information 2013.
Bethesda: American Society of Health-System Pharmacists;
2013. p. 3530e5.
9. Wu FL, Shen LJ, Yang CC, Chen CH. Stability of extempora-
neous suspensions of co-trimoxazole. Chin Pharm J 1999;51:
93e102.
10. Wu FL, Chen RL, Lee SS, Sun SW. Determination of sirolimus in
blood by high-performance liquid chromatography with ultra-
violet detection e experience and review. J Food Drug Anal
2005;13:1e11.
11. Yang HL, Shen LJ, Hunag CF, Lin CY, Chen WH, Hsieh YT, et al.
Are brand-name drugs of better quality than generics?
Research at a medical center in Taiwan. J Food Drug Anal 2012;
20:1e6.
12. Lin CY, Shen LJ, Huang CF, Yang HL, Chen YY, Lin Wu FL.
Beyond-use date of the extemporaneous morphine hydrochlo-
ride oral solution. J Food Drug Anal 2013;21:142e6.
13. United States Pharmacopeia Convention. Chlorhexidine gluco-
nate solution. In: United States Pharmacopeia Convention,
editor. The United States pharmacopeiaenational formulary
(USP 36-NF 31). Rockville: United States Pharmacopeia
Convention; 2013. p. 2944e5.
14. United States Pharmacopeia Convention. Particulate matter in
ophthalmic solutions. In: United States Pharmacopeia
Convention, editor. The United States pharmacopeiaenational
Formulation of an extemporaneous chlorhexidine eye drop 1169formulary (USP 36-NF 31). Rockville: United States Pharmaco-
peia Convention; 2013. p. 353.
15. United States Pharmacopeia Convention. Pharmaceutical
dosage formsdophthalmic preparations. In: United States
Pharmacopeia Convention, editor. The United States
pharmacopeia-national formulary (USP 34-NF 29). Rockville:
United States Pharmacopeia Convention; 2011. p. 694e706.16. Chowhan M, Lang JC, Paul Missel. Ophthalmic preparations. In:
AllenLV,editor.Remington:the scienceandpracticeofpharmacy.
22nd ed. Philadelphia: Pharmaceutical Press; 2013. p. 911e29.
17. Edelhauser HF. The balance between corneal transparency and
edema. Invest Ophthalmol Vis Sci 2006;47:1755e67.
18. Po HN, Senozan NM. The HendersoneHasselbalch equation: its
history and limitations. J Chem Educ 2001;78:1499e503.
